Antares Pharma (ATRS) Tops Q4 EPS by 1c

Antares Pharma (NASDAQ: ATRS) reported Q4 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $14 million versus the consensus estimate of $15.65 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
• FedEx (FDX) PT Lowered to $424 at Bernstein SocGen Group
• Hyperscale Data launches $300M at-the-market stock offering